Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Portnoy (NPI 1679529473)

Field	Value
Entity Type	Individual
Organization	David Portnoy
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 25, 2006

Payer Source	Total Paid
Medicare	$6.5M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused oncology practice: total Medicare revenue is $6.5M and there is no Medicaid billing on file, indicating a single-payer footprint concentrated on fee-for-service Medicare. The absence of state Medicaid activity suggests payor mix and network-risk are largely tied to Medicare payment dynamics rather than dual-payer strategies.

Revenue is highly concentrated in a few high-cost immunotherapy agents: the precomputed top 3 Medicare codes account for 55.1% of this provider's total Medicare revenue, led by J9271 ($1.8M revenue (29.6% of this provider's total Medicare revenue)), J9299 ($1.1M revenue (17.9% of this provider's total Medicare revenue)), and J9228 ($474.5K revenue (7.6% of this provider's total Medicare revenue)). This concentration means changes in utilization, reimbursement, or utilization management for these agents could materially affect overall revenue.

The CPT/HCPCS mix signals an infusion-based hematology/oncology operation focused on checkpoint inhibitors and other parenteral oncology therapies: high-revenue drugs include J9271 (pembrolizumab), J9299 (nivolumab), J9022 (atezolizumab), J9144 (daratumumab), and administration codes such as 96413 and 96367. Presence of 96413 ($92.3K revenue (1.5% of this provider's total Medicare revenue)) and 96367 ($22.3K revenue (0.4% of this provider's total Medicare revenue)) confirms frequent in-office intravenous chemotherapy/immunotherapy administration rather than solely oral or external infusion center delivery.

The provider shows a dominant national presence for several key drugs: J9271 ranks #23 of 1841 providers nationally (99th percentile; notably above typical national volume for this code) and J9299 ranks #19 of 505 providers nationally (96th percentile; notably above typical national volume for this code). Other notable high-volume positions include M0010 (ranks #8 of 544 providers nationally (99th percentile; notably above typical national volume for this code)) and 96367 (ranks #57 of 4032 providers nationally (99th percentile; notably above typical national volume for this code)), indicating this clinician is a major national-volume biller for select oncology service items.

There are pronounced statistical outliers in procedure-level activity: 96413 is flagged as an extreme outlier, far above typical national volume for this code (rank #73 of 7514 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code)) and 96367 is also in the 99th percentile for national volume. These outlier signals reflect concentrated operational throughput of infusion-based oncology services and may warrant further review when benchmarking throughput, scheduling, and drug inventory needs.

Supportive-care and ancillary oncology services are also present but represent smaller revenue slices: J2506 (pegfilgrastim) shows $78.3K revenue (1.3% of this provider's total Medicare revenue), J0897 (denosumab) $281.9K revenue (4.5% of this provider's total Medicare revenue) and routine labs like 85025 contribute $20K revenue (0.3% of this provider's total Medicare revenue). This mix is consistent with management of treatment-related neutropenia, bone health, and ongoing monitoring typical in a systemic therapy practice.

Operational scale is large in claim volume for multiple codes, supporting the picture of a high-throughput infusion practice: examples include 42.8K claims for J9271 and 46.3K claims for J9299 as reported, plus 33.7K claims for J0881 and 34.5K claims for J1439 for lower-dollar items. These claim-counts suggest heavy clinical throughput and substantial drug administration logistical requirements, which have implications for staffing, drug acquisition, and revenue cycle operations.

This clinician has long-tenured enrollment in Medicare (NPI enumerated 2006-05-25 (~20 years ago)), indicating established participation and likely operational stability in the Medicare program. Tenure combined with the concentrated revenue mix and national high-percentile rankings positions this provider as an experienced, high-volume oncology billing entity whose financial performance will be sensitive to shifts in utilization and reimbursement for major immunotherapy agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

113 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	42,800	$40	$1.8M
J9299	Injection, nivolumab, 1 mg	46,340	$20	$1.1M
J9228	Injection, ipilimumab, 1 mg	3,650	$130	$474.5K
J9022	Injection, atezolizumab, 10 mg	6,960	$60	$445.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,540	$40	$362.5K
J1930	Injection, lanreotide, 1 mg	6,840	$40	$301K
J0897	Injection, denosumab, 1 mg	15,660	$20	$281.9K
J9173	Injection, durvalumab, 10 mg	4,390	$60	$272.1K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	950	$160	$150.1K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,120	$40	$148.3K

Showing 1–10 of 113

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 113 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

David Portnoy — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

113 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	50	17,400	$40	$776.1K
J9299	1	20	21,010	$20	$487.5K
J9228	1	10	3,650	$130	$475.6K
J9144	12	20	10,080	$40	$466.3K
J9022	1	10	6,960	$60	$444.7K
J9173	1	10	3,720	$60	$211.7K
J1569	9	30	3,030	$40	$175.2K
J1930	1	10	2,880	$40	$162K
J9047	4	10	3,090	$40	$117.8K
J2353	1	10	650	$150	$106.3K

Showing 1–10 of 113

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Portnoy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0
Sonia Benn	MS	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as David Portnoy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

David Portnoy — Billing Profile & Reimbursement Data

Sign up for David Portnoy — Billing Profile & Reimbursement Data policy alerts

David Portnoy — Billing Profile & Reimbursement Data

Sign up for David Portnoy — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References